Logo image of LRMR

LARIMAR THERAPEUTICS INC (LRMR) Stock Fundamental Analysis

NASDAQ:LRMR - Nasdaq - US5171251003 - Common Stock - Currency: USD

3.74  +0.43 (+12.99%)

After market: 3.9 +0.16 (+4.28%)

Fundamental Rating

2

Overall LRMR gets a fundamental rating of 2 out of 10. We evaluated LRMR against 551 industry peers in the Biotechnology industry. While LRMR has a great health rating, there are worries on its profitability. LRMR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LRMR had negative earnings in the past year.
LRMR had a negative operating cash flow in the past year.
LRMR had negative earnings in each of the past 5 years.
LRMR had a negative operating cash flow in each of the past 5 years.
LRMR Yearly Net Income VS EBIT VS OCF VS FCFLRMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -55.96%, LRMR is in line with its industry, outperforming 45.55% of the companies in the same industry.
LRMR has a Return On Equity (-66.01%) which is in line with its industry peers.
Industry RankSector Rank
ROA -55.96%
ROE -66.01%
ROIC N/A
ROA(3y)-35.58%
ROA(5y)-42.34%
ROE(3y)-41.34%
ROE(5y)-50%
ROIC(3y)N/A
ROIC(5y)N/A
LRMR Yearly ROA, ROE, ROICLRMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LRMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LRMR Yearly Profit, Operating, Gross MarginsLRMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, LRMR has more shares outstanding
LRMR has more shares outstanding than it did 5 years ago.
LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LRMR Yearly Shares OutstandingLRMR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
LRMR Yearly Total Debt VS Total AssetsLRMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of 1.42, we must say that LRMR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LRMR (1.42) is better than 68.24% of its industry peers.
LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.42
ROIC/WACCN/A
WACCN/A
LRMR Yearly LT Debt VS Equity VS FCFLRMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 7.48 indicates that LRMR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.48, LRMR is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
LRMR has a Quick Ratio of 7.48. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.48, LRMR is doing good in the industry, outperforming 68.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.48
Quick Ratio 7.48
LRMR Yearly Current Assets VS Current LiabilitesLRMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LRMR have decreased strongly by -53.61% in the last year.
EPS 1Y (TTM)-53.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LRMR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.68% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-50.68%
EPS Next 2Y-25.68%
EPS Next 3Y-9.06%
EPS Next 5Y-5.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LRMR Yearly Revenue VS EstimatesLRMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LRMR Yearly EPS VS EstimatesLRMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LRMR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LRMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LRMR Price Earnings VS Forward Price EarningsLRMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LRMR Per share dataLRMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as LRMR's earnings are expected to decrease with -9.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.68%
EPS Next 3Y-9.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LRMR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (8/5/2025, 6:01:59 PM)

After market: 3.9 +0.16 (+4.28%)

3.74

+0.43 (+12.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners103.64%
Inst Owner Change0.44%
Ins Owners1.36%
Ins Owner Change0%
Market Cap239.47M
Analysts88.89
Price Target20.77 (455.35%)
Short Float %9.74%
Short Ratio5.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.48%
Min EPS beat(2)-39.14%
Max EPS beat(2)-7.82%
EPS beat(4)1
Avg EPS beat(4)-4.72%
Min EPS beat(4)-39.14%
Max EPS beat(4)37.25%
EPS beat(8)3
Avg EPS beat(8)-4.76%
EPS beat(12)7
Avg EPS beat(12)4.99%
EPS beat(16)9
Avg EPS beat(16)3.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.75%
PT rev (3m)0.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.33%
EPS NY rev (1m)0.43%
EPS NY rev (3m)-4.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)-2.05
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.96%
ROE -66.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.58%
ROA(5y)-42.34%
ROE(3y)-41.34%
ROE(5y)-50%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.48
Quick Ratio 7.48
Altman-Z 1.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)82.04%
Cap/Depr(5y)77.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70.37%
EPS Next Y-50.68%
EPS Next 2Y-25.68%
EPS Next 3Y-9.06%
EPS Next 5Y-5.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-107.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.56%
EBIT Next 3Y-10.15%
EBIT Next 5Y49.4%
FCF growth 1Y-215.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-214.96%
OCF growth 3YN/A
OCF growth 5YN/A